Epithelial alarmins: IL-25, IL-33 and TSLP
- Molecule
When skin, airway or gut lining is damaged, it releases three alarm signals that start allergic (type 2) inflammation before any IgE exists.
What it is
IL-25, IL-33 and thymic stromal lymphopoietin (TSLP) are released by epithelial cells after injury, allergen exposure, viral infection or pollution. They activate group 2 innate lymphoid cells, mast cells and dendritic cells, which push the immune response toward type 2 (IL-4, IL-5, IL-13). They sit upstream of asthma, atopic dermatitis and helminth defence, and blocking TSLP is now a treatment for severe asthma.
Step by step
- An allergen with protease activity, a virus, smoke or scratching injures the epithelium.
- Epithelial cells release IL-33 (stored in the nucleus, set free by damage), TSLP and IL-25.
- ILC2s respond within hours with IL-5 and IL-13: eosinophils arrive and mucus increases.
- TSLP-conditioned dendritic cells carry allergen to the lymph node and drive Th2 differentiation.
- Th2 cells make IL-4 for IgE class switching; IgE then arms mast cells for the next exposure.
- In the gut, tuft cells sense helminths and release IL-25, starting a ‘weep and sweep’ response.
The three alarmins
| Alarmin | Released by | Receptor | Notes |
|---|---|---|---|
| IL-33 | Damaged or necrotic epithelial and endothelial cells | ST2 (IL-1 receptor family) | IL-1 family member; soluble ST2 is a heart-failure biomarker |
| TSLP | Keratinocytes, airway and gut epithelium | TSLP receptor + IL-7Rα | Target of tezepelumab in severe asthma |
| IL-25 (IL-17E) | Tuft cells in the gut, airway epithelium | IL-17RB | Key in the anti-helminth tuft-cell circuit |
Clinical notes
- Tezepelumab (anti-TSLP) reduces severe asthma exacerbations, including in patients without high blood eosinophils.
- Antibodies against IL-33 or its receptor are being studied for asthma and COPD.
- In atopic dermatitis, scratching releases TSLP and IL-33, which feed the itch–inflammation cycle.
- House-dust-mite allergens are proteases that disrupt the airway barrier and trigger alarmin release.
Common traps
- Allergic inflammation starts with IgE: IgE comes later, and epithelial alarmins and ILC2s start type 2 inflammation without any antigen specificity.
- IL-25 is an IL-1 family member like IL-33: IL-25 is IL-17E of the IL-17 family, while IL-33 belongs to the IL-1 family.
- Anti-TSLP only helps eosinophilic asthma: tezepelumab acts upstream, so it reduces exacerbations even in patients with low blood eosinophils.
- IL-33 is secreted like other cytokines: it is stored in the nucleus and released when cells are damaged or die, which makes it a true alarm.
Test yourself
Think of the answer, then tap the question to see it.
Why can tezepelumab help a severe asthmatic whose blood eosinophils are low, when anti-IL-5 drugs do not?
TSLP sits upstream of several type 2 pathways (ILC2, Th2, mast cells), so blocking it damps inflammation beyond eosinophils.
Why does scratching worsen atopic dermatitis immunologically, not just mechanically?
Damaged keratinocytes release TSLP and IL-33, which activate ILC2s, Th2 cells and itch neurons, feeding the itch–inflammation cycle.
A worm infection triggers mucus and gut contractions. Which epithelial cell starts this and with which alarmin?
Tuft cells sense the helminth and release IL-25, which activates ILC2s to make IL-13 (weep and sweep).
Elsewhere in DurgiPedia
Connections
In Pharmacology2
Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.
Sources: Asthma (MedlinePlus, US National Library of Medicine, 2024); Eczema (MedlinePlus, US National Library of Medicine, 2024).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
